Research Triangle Park, N.C. – Jan. 3, 2023 – Opus Genetics, a patient-first, clinical-stage gene therapy company developing treatments for inherited retinal diseases, today announced that Ben Yerxa, Ph.D., Chief Executive Officer of Opus, will present a company overview and provide an update on Opus’ gene therapy programs for inherited retinal diseases at the Biotech Showcase™ 2023 in San Francisco.
Details of the presentation are as follows:
Date: Monday, January 9, 2023
Time: 10:15 a.m. PST
Location: Hilton San Francisco Union Square, 333 O’Farrell Street, San Francisco, CA 94102
Track: Franciscan A (Ballroom Level)
Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and investors that fosters investment and partnership opportunities. The conference takes place each year during the course of one of the industry’s largest gatherings and busiest weeks. For more information or to register, visit www.biotechshowcase.com.
About Opus Genetics
Opus Genetics is a clinical-stage gene therapy company for inherited retinal diseases with a unique model and purpose. Backed by Foundation Fighting Blindness’ venture arm, the RD Fund, Opus combines unparalleled insight and commitment to patient need with wholly owned programs in numerous orphan retinal diseases. Its AAV-based gene therapy portfolio tackles some of the most neglected forms of inherited blindness while creating novel orphan manufacturing scale and efficiencies. Based in Research Triangle Park, N.C., the company leverages knowledge of the best science and the expertise of pioneers in ocular gene therapy to transparently drive transformative treatments to patients. For more information, visit www.opusgenetics.com.
Opus Media Contact:
Heather Anderson
6 Degrees
919-827-5539
